CORRECTED: Endo Inks $193M Deal Over Off-Label Lidoderm Marketing

Law360, Philadelphia (February 21, 2014, 4:42 PM EST) -- Endo Health Solutions Inc. agreed to pay nearly $193 million on Friday to settle civil whistleblower claims and criminal allegations that off-label promotion of the adhesive pain-relief patch Lidoderm induced health care providers to submit false claims for reimbursement to Medicare, Medicaid and other federal programs.

The agreement, which includes $171.9 million in civil penalties and a $20.8 criminal forfeiture, stems from a trio of whistleblower suits brought by employees against the company in Pennsylvania federal court alleging that the medication was promoted off-label to alleviate...
To view the full article, register now.